APOKYN

DRUG3 trials

Sponsors

MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals, Sumitomo Pharma America, Inc.

Conditions

AkinesiaDelayed Levodopa OnsetHypomobilityMotor SymptomsParkinson DiseaseParkinson's Disease

Phase 2

A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by OFF Episodes

CompletedNCT03292016

Sumitomo Pharma America, Inc.Parkinson Disease

Start: 2017-08-22End: 2019-03-05Updated: 2020-08-13

Phase 4

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

CompletedNCT01770145

MDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsAkinesia, Delayed Levodopa Onset, Hypomobility +2

Start: 2012-12-31End: 2014-04-30Updated: 2023-08-14

Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®

TerminatedNCT02549573

MDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsMotor Symptoms, Parkinson's Disease

Start: 2016-01-31End: 2016-12-31Updated: 2023-09-01

Related Papers

Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and "OFF" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study.

2021-05-1523 citations